- Home
- PRAX vs NOVT Comparison
PRAX vs NOVT Comparison
Compare PRAX & NOVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | NOVT |
|---|---|---|
| Founded | 2015 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 3.8B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | NOVT |
|---|---|---|
| Price | $286.98 | $111.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 1 |
| Target Price | ★ $373.79 | $133.00 |
| AVG Volume (30 Days) | ★ 771.9K | 443.1K |
| Earning Date | 11-05-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.46 |
| Revenue | $7,463,000.00 | ★ $960,311,000.00 |
| Revenue This Year | N/A | $5.10 |
| Revenue Next Year | $12,467.71 | $6.75 |
| P/E Ratio | ★ N/A | $76.12 |
| Revenue Growth | ★ 364.98 | 4.07 |
| 52 Week Low | $26.70 | $98.27 |
| 52 Week High | $317.72 | $155.39 |
Technical Indicators
Market Signals| Indicator | PRAX | NOVT |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 41.06 |
| Support Level | $285.95 | $118.42 |
| Resistance Level | $317.72 | $124.98 |
| Average True Range (ATR) | 12.78 | 3.98 |
| MACD | -1.09 | -0.90 |
| Stochastic Oscillator | 43.76 | 8.03 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About NOVT Novanta Inc.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.